Glutamate receptor ionotropic, NMDA 2B

BE0000417ProteinHumansGRIN2B

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:24272827, PubMed:24863970, PubMed:26875626, PubMed:26919761, PubMed:27839871, PubMed:28095420, PubMed:28126851, PubMed:38538865, PubMed:8768735). It is acted on by 26 drugs in DrugBank.

Gene name
GRIN2B
UniProtKB entry
Q13224Swiss-Prot
Cellular location
Cell membrane
Residues / weight
1,484 residues · 166,366 Da
Also known as
GluN2B · Glutamate [NMDA] receptor subunit epsilon-2 · hNR3 · N-methyl D-aspartate receptor subtype 2B · N-methyl-D-aspartate receptor subunit 3

Resolves to

Protein
UniProtQ13224UniProt nameNMDE2_HUMAN
Gene
HGNCHGNC:4586NCBI Gene2904GenBank1899202GeneCardsGRIN2B
Pharmacology
IUPHAR/GtoPdb457KEGGhsa:2904
Structure
PDB10EYPDB10EZPDB10FD
Drugs

What you can answer from here — as of September 07, 2019

26DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
30GO termsFunction, process and component, as structured annotations
Sign in
4Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
57+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Glutamate receptor ionotropic, NMDA 2B, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In